Senseonics (NYSE:SENS) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Senseonics (NYSE:SENS) in a research note issued to investors on Wednesday morning. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $2.00 price target on shares of Senseonics in a research report on Wednesday, August 14th.

Senseonics Price Performance

Senseonics stock opened at $0.34 on Wednesday. The business’s 50 day simple moving average is $0.37 and its 200 day simple moving average is $0.41. Senseonics has a 12 month low of $0.32 and a 12 month high of $0.75. The company has a market cap of $179.44 million, a price-to-earnings ratio of -2.41 and a beta of 0.79. The company has a current ratio of 3.11, a quick ratio of 2.89 and a debt-to-equity ratio of 59.17.

Senseonics (NYSE:SENS) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. The company had revenue of $4.87 million during the quarter, compared to the consensus estimate of $4.86 million. Sell-side analysts forecast that Senseonics will post -0.13 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System bought a new position in Senseonics in the 1st quarter valued at $91,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Senseonics by 30.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock worth $483,000 after purchasing an additional 211,128 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Senseonics by 16.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after purchasing an additional 51,000 shares during the last quarter. Vanguard Group Inc. raised its stake in Senseonics by 0.7% in the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock valued at $11,963,000 after purchasing an additional 155,715 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Senseonics during the first quarter valued at approximately $162,000. Institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.